PulseCath BV. is a Netherlands based medical device company that develops, manufactures and markets circulatory support systems.
The company, formed in 2007, has developed unique and proprietary platform technology to provide a short-term circulatory support system for cardiologists and cardiac surgeons.
The iVAC 2L is a short term, fully percutaneous, 17Fr transfemoral LVAD that effectively generates blood flow up to 2 liters per minute.
By actively unloading the ventricle, the iVAC 2L provides critical hemodynamic support during high-risk revascularization procedures, in cases of acute myocardial infarction and cardiogenic shock and for high-risk patients.
Main Features:
The iVAC 2L incorporates a patented rotating 2 way valve which is connected to an extra corporeal membrane pump via a 17Fr. single lumen, 100 cm long catheter. It can be used with any standard IABP console and does not require dedicated hardware.
When the heart is in the systolic phase, blood is aspirated from the left ventricle through the catheter tip and lumen into the membrane pump.
During the diastolic phase the membrane pump ejects the blood back through the catheter, subsequently opening the catheter valve and delivering the blood to the ascending aorta through the side outflow port, thereby creating an “extra beat of the heart”.
The pulsatile synchronization between the closing of the aortic valve and the opening of the catheter valve, ensures that aortic valve function is not impaired.
The iVAC 2L directly unloads the heart by active aspiration from the left ventricle, and simultaneously creates a counter pulsating flow in the ascending aorta.
The iVAC 2L is intended for use in patients with impaired left ventricular function which require left ventricular mechanical circulatory support for up to 24 hr.
The iVAC 2L tip should be positioned in the left ventricular cavity through the femoral artery.
Since our beginnings we have always worked with quality products and we have experienced professionals allowing maximum grade in order to be always at the forefront.
All our products are high-tech standards, with innovation and keeping a strong presence in international markets.
cNovate Medical BV operates globally and specializes in the research, development, manufacturing and sales of cardiovascular and endovascular treatment devices.
We are not working alone. Part of our success is due to working closely with customers, patients, industry partners, leaders and government agencies to realize the vision of better, simpler and more accessible healthcare.
PulseCath® is focused on developing ground-breaking technologies designed to assist the life sustaining pumping functions of the failing heart.
PulseCath BV. is a Netherlands based medical device company that develops, manufactures and markets circulatory support systems. The company, formed in 2007, has developed unique and proprietary platform technology to provide a short-term circulatory support system for cardiologists and cardiac surgeons.
Super selective and targeted embolizations
Interventional Radiologists are finding confidence through a greater sense of predictability while using Varian microspheres. Designed with elasticity to allow smooth delivery and size calibrated to enable deep tumor coverage, our array of tightly calibrated bead sizes is expanding the possibilities of embolization procedures and the type of patients that can benefit.
The blueflow Venous Stent is indicated for the treatment of venous outflow obstructions in the lower extremities. With its closed cell design, blueflow Venous Stent is highly flexible. The blueflow Venous Stent is available in different configurations.
Many people suffer from venous diseases. Varicose veins and spider veins are terms that almost everyone knows. If varicose veins or even venous ulcers (Ulcus Cruris) occur again despite a varicose vein treatment, these are often the consequences of an obstruction in the pelvic vein caused by a thrombosis.
Embolx is an emerging commercial-stage medical device company in Silicon Valley developing microcatheters for arterial embolization procedures. Embolx is committed to dramatically improving the treatment of a variety of conditions including cancerous tumors, benign prostatic hyperplasia and uterine fibroids. The Sniper® balloon occlusion microcatheter sets a new standard for precise embolic delivery and superior target filling by controlling pressure to direct blood flow while protecting non-target surrounding tissues. Embolx is a privately held company.
